# INTRODUCTION OF HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION INTO SOUTH KOREA

S.S. KIM<sup>1,3</sup>, E.Y. KIM<sup>1</sup>, K.Y. PARK<sup>1</sup>, S.D. SUH<sup>1</sup>, H.K. PARK<sup>1</sup>, Y.O. SHIN<sup>2</sup>, M. BAE<sup>3</sup>, J.S. LEE<sup>1\*</sup>

<sup>1</sup>Center for AIDS Research, Department of Virology, National Institute of Health, 5 Nokbun-dong Eunpyung-gu, Seoul, 122-701 South Korea; <sup>2</sup>Department of Microbiology, Kangwon National University College of Medicine, Chunchon, South Korea; <sup>3</sup>Department of Biological Science, Ewha Womans University, South Korea

Received November 23, 1999; accepted December 1, 1999

Summary. - Although human immunodeficiency viruses 1 and 2 (HIV-1 and HIV-2) share mode of transmission, their epidemiologic characteristics differ and international spread of HIV-2 has been limited. To investigate the extent of HIV-2 infection in South Korea and to clarify the characteristic of HIV-2 isolates, we describe epidemiological, serological and genetic analyses of five HIV-2 isolates from South Korea. Five of 964 HIV antibody-positive serum specimens showed positive reactivity by HIV1/2 enzyme immunoassay (EIA), HIV-2 Western blot analysis, HIV-2 particle agglutination (PA) test and line immunoassay (LIA) but negative or indeterminate one by HIV-1 PA test and HIV-1 Western blot analysis. To confirm HIV-2 infection by genetic analysis, reverse transcription-polymerase chain reaction (RT-PCR) was performed on five HIV-2 seropositive samples. PCR products from gag (197 bp) and env gene regions (137 bp) were obtained with three of the five samples with HIV-2 specific gag primers and with all the five samples with env primers. To obtain larger sequences for a more comprehensive phylogenetic analysis, we performed PCR for a 1191 bp env region of HIV-2 but only two such products were obtained. For the phylogenetic analysis, three 197 bp gag and two 1191 bp env PCR products were cloned and sequenced. Based on the gag and env sequences alignments, three isolates (KR4063, KR7051 and KR8091) were clustered phylogenetically within HIV-2 subtype A. In conclusion, HIV-2 virus is present in South Korea and was detected in five subjects. Furthermore, the prevalence of HIV-2 infection should be monitored continuously in South Korea to assess the spread of this virus and to assist in the diagnosis of HIV infection.

Key words: HIV-2; PCR; nucleotide sequencing; serological diagnosis; South Korea

### Introduction

Since HIV-2 had been isolated in western Africa (Clavel et al., 1986), it has spread virtually worldwide. However,

HIV-2 infection is confined to western Africa and most cases of HIV-2 infection outside Africa occurred in France and Portugal (De Cock *et al.*, 1993). Compared to HIV-1, sexual and perinatal transmission of HIV-2 is much less efficient than that of HIV-1 as a result of a low viral burden during the relatively long asymptomatic period (Kanki *et al.*, 1994; Marlink *et al.*, 1994; Simon *et al.*, 1993). Therefore, the number of HIV-2-infected individuals has remained relatively small, bound to limited geographical regions compared to HIV-1 infection (De Cock *et al.*, 1993; Schim *et al.*, 1999).

Molecular epidemiology studies have led to classification of HIV-2 into six specific subtypes from A to F (Chen *et al.*,

\*Corresponding author. E-mail: aidshiv@nuri.net; fax: +822-3591397

Abbreviations: DTT = dithiothreitol; EIA = enzyme immunoassay; gp = glycoprotein; HIV-1 = human immunodeficiency virus 1; HIV-2 = human immunodeficiency virus 2; LIA = line immunoassay; PA = particle agglutination; PBMC = peripheral blood mononuclear cell; PCR = polymerase chain reaction; RT-PCR = reverse transcription-PCR

Table 1. Primer pairs selected for nested PCR of HIV-2 proviral DNA and cDNA

Region	Position (nt)	Sequence (5'-3')	PCR product size (bp)	Reaction conditions	Reference
Outer pair				1 min, 94°C	
Gag A	539-561	GTGGGAGATGGGCGCGAGAAACT		1 min, 94 °C; 45 secs, 55 °C; 45 secs, 70 °C (35 cycles)	Grankvist et al. (1992)
Gag B Inner pair	1062-1085	GGATTTCAGGCACTCTCAGAAGGC		3 mins, 70 °C 1 min, 94 °C	
Gag C	637-660	TAAAACATATTGTGTGGGCAGCGA	197	1 min, 94 °C; 45 secs, 55 °C; 45 secs, 70 °C (25 cycles)	Grankvist et al. (1992)
Gag D Outer pair	810-833	CACGCAGAAGAGAAAGTGAAAGAT		3 mins, 70 °C 1 min, 94 °C	
Env A	7782-7805	GGGATAGTGCAGCAACAGCAACAG		1 min, 94 °C; 45 secs, 55 °C; 45 secs, 70 °C (35 cycles)	Grankvist et al. (1992)
Env B Inner pair	8259-8281	AAGGGCTATAGGCCTGTTTTCTC		3 mins, 70 °C 1 min, 94 °C	
Env C	7837-7861	TGTTGCGACTGACCGTCTGGGGAAC	137	1 min, 94 °C; 45 secs, 55 °C; 45 secs, 70 °C (25 cycles)	Grankvist et al. (1992)
Env D Outer pair	7950-7973	GTCTGCCACACTACTGTACCATGG		3 mins, 70 °C 1 min, 94 °C	
Env E	6300-6324	ATACAGTGCTTRCCAGACAATGATG		1 min, 94 °C; 1 min, 55 °C; 1 min, 70 °C (3 cycles)	Damond et al. (1998)
Env B	8259-8281	AAGGGCTATAGGCCTGTTTTCTC		15 secs, 94 °C; 45 secs, 55 °C; 45 secs, 70 °C (32 cycles), 5 mins, 70 °C	
Inner pair				1 min, 94 °C	
Env F	6783-6804	TCATGTGAYAARCAYTATTGGG	1191	1 min, 94 °C; 1 min, 55 °C; 1 min, 70 °C (3 cycles)	Damond <i>et al.</i> (1998)
Env D	7950-7973	GTCTGCCACACTACTGTACCATGG		15 sees, 94 °C; 45 sees, 55 °C; 45 sees, 70 °C (25 cycles), 5 mins, 70 °C	

1997). The majority of isolates were classified as A subtype, with most of the remaining isolates belonging to B subtype. The virological characteristic and pathogenicity of A subtype have been described (Gao *et al.*, 1994). But for the other subtypes, studies of relative distribution and natural history are scarce. For vaccine development, biological and genetic characterization of HIV-2 isolates must be conducted as well as that of HIV-1 isolates. In addition, prevailing strains by geographical region should be monitored by molecular epidemiology.

According to periodical reports of the Ministry of Health and Welfare of South Korea, 964 South Koreans with HIV have been confirmed as of June 1999. A HIV-2 infection among these subjects was possible since 27% (260/964) of them have been infected abroad by sexual contact or blood transfusion. However, the HIV-2 infection in South Korea has not been monitored until now. With the detection of HIV-2 infection, we can confirm the spreading of HIV-2 in South Korea and establish a HIV testing strategy in which HIV-2 is included. To determine the scale of HIV-2 infection in South Korea and to clarify the characteristics of HIV-2 isolates, we performed serological and genetic analyses on five HIV-2 infection detected by serological and genetical analyses in South Korea.

#### Materials and Methods

Subjects. The National Institute of Health of South Korea has performed confirmation of HIV infection on serum specimens showing repeatedly a positive reaction by EIA from over 300 testing sites such as public health centers, blood banks and quarantine stations in South Korea since 1985. Every year about two thousand specimens were tested. According to the test results from 1985 to June 1999, 964 subjects have been confirmed as HIV-seropositive. Among them, five showed positive reactivity by HIV-2 EIA, HIV-2 PA test, and HIV-2 Western blot analysis, and indeterminate reactivity by HIV-1 Western blot analysis.

Serological assays. All referred sera were subjected to HIV-1/HIV-2 EIA (Vironostika\* HIV Uni-form II plus 0; Organon Teknika, Wellcozyme\* HIV1+2; Murex) and PA (Serodia\* – HIV, Fujirebio Inc.) test using commercial kits according to the manufacturer's instructions. If sera positive by HIV1/2 EIA were positive also with HIV-1 PA, they were retested with a HIV-1 Western blot kit (Cambridge Biotech Corp.). The sera positive by HIV-2 PA were retested with a HIV-2 Western blot kit (New Lav Blot II; Sanofi Diagnostic Pasteur). The five HIV-2-positive sera were also tested with (1) a HIV-1/2 Western blot kit (Gene Lab) based on a synthetic peptide from HIV-2 glycoprotein (gp 36) as well as on whole HIV-1 lysates, and (2) by a LIA (PEPTI-LAV 1, 2; Sanofi Diagnostic Pasteur) based on synthetic peptides from a HIV-1 transmembrane protein (gp41) and a HIV-2 transmembrane protein (gp36).

Table 2. Epidemiological history of subjects infected with HIV-2

Surject	Year of HIV-2 detection	Age <sup>a</sup> / Sex	Occupation	Most likely place of infection	Probable mode of transmission	Disease status
KR8092	'98	19/M	Unknown	Korea	Homosexual contact	Asymptomatic
KR7051	'97	54/M	Sailor	Las Palmas de Gran Canaria	Heterosexual contact with foreign prostitute	
KR4075	'94	39/F	Housewife	Korea	Heterosexual contact	Asymptomatic
KR4063	'94	46/M	Sailor	Senegal	Heterosexual contact with foreign prostitute	
KR1010	'91	28/M	Sailor	Las Palmas de Gran Canaria	Heterosexual contact with foreign prostitute	Asymptomatic

aYears.

Table 3. Serological profiles of the sera from HIV-2-infected subjects

Subject	HIV1/2		HIV-I		HIV-2	
	EIAª	LIA(HIV1/HIV2)	PA test	Western blot analysis	PA test (titer)	Western blot analysis
KR8091	>6.41	ND/++		(gp160),(p31),p24	++ (32,768)	gp140,105,36,p68,56,26,16
KR7051	>7.53	ND/++	_	(gp160)	++ (524,288)	gp140,105,(p68,56),26,16
KR4075	>5.88	±/++	_	(gp160),p31,24	++ (131,072)	gp140,105,36,p68,56,26,16
KR4063	>9.19	±/++	±	gp160,(p66,51),p31,55,24	++ (262,144)	gp140,105,36,p68,56,26,16
KR1010	1.416	± / ++	-	gp160,p66,51,31,p55,24	++ (16,384)	gp140,105,36,p68,56,26,16

<sup>&</sup>lt;sup>a</sup>Absorbancy of sample/cut off absorbancy.

RNA extraction from plasma and RT-PCR. Total RNA was extracted from 250 μl aliquots of plasma with Isogen-LS, an acidic guanidinum-thiocyananate-based reagent (Molecular Research Center Inc.) according to a modification of the method of Nakamura et al. (1993). RNA was reverse transcribed in a 20 μl reaction mixture containing 5 U of reverse transcriptase, 1.3 U of RNase inhibitor (Takara Shuzo), 0.2 mmol/l dNTPs, 10 x PCR buffer, 0.01 mol/l dithiothreitol (DTT), and 1 μmol/l antisense primer at 42°C for 60 mins and at 99°C for 5 mins. The obtained cDNA (10 μl) was amplified in a 40 μl reaction mixture containing 10 x PCR buffer, 0.2 mmol/l dNTPs, 1.5 μmol/l sense primer, 0.5 μmol/l antisense primer, and 1.5 U of Taq polymerase (Boehringer Mannheim) according to the nested PCR conditions. The sense and antisense primers are described in Table 1.

DNA extraction from peripheral blood mononuclear cells (PBMCs) and PCR. DNA was extracted from uncultured patients PBMCs with a nucleic acid extraction kit (IsoQuick, ORCA Research Inc). PCR was carried out in a total volume of 50 μl containing 1 μg of genomic DNA, 5 μl of 10 x PCR buffer, 0.2 mmol/l dNTPs, 0.3 mmol/l MgCl<sub>2</sub>, 1.5 μmol/l primers, and 2.5 U of Taq polymerase (Boehringer Mannheim) using a DNA Thermal Cycler (Perkin Elmer Cetus 2400). The amplification cycles are described in Table 1. The subsequent nested PCR (25 cycles) was carried out under the same conditions as the first PCR with 2 μl of the first PCR product in a volume of 50 μl. DNA isolated from PBMCs of healthy blood donors was used as a control. Nested PCR products were analyzed on a 3.5% or 1% GTG agarose gel after ethidium bromide staining.

DNA sequencing and phylogenetic analysis. Nested PCR products were cloned into pCR\*\* 2.1 Topo-vectors (Invitrogen) by T/A

overhang. Recombinant clones containing HIV-2 fragments were purified with 20% polyethylene glycol 8000 and 2.5 mol/l NaCl and sequenced using fluorescent-labeled terminators (ABI Prism 377 DNA sequencer, Applied Biosystems). One or two clones per PCR product were sequenced for the 197 bp gag fragment and at least two clones were sequenced for the 1191 bp env fragment. Phylogenetic relationships of three South Korean isolates to previously published HIV-2 strains were estimated from comparisons of their nucleotide sequences. Sequences were aligned using Clustal W. MegAline (Dnastar Inc.). Phylogenetic relationships were computed from the distances by the neighbor-joining method.

### Results

Epidemiological and clinical characteristics of HIV-2 infected subjects

Epidemiological and clinical characteristics of the five HIV-2 infected subjects are shown in Table 2. Three males, sailors, were most likely infected with the virus by heterosexual contact in regions of western Africa such as Senegal and Las Palmas de Gran Canaria. The fourth male (KR8092) very likely contracted HIV-2 from KR7051 through homosexual contact. The only female was a wife of KR4063. Four subjects were healthy at the time of the diagnosis of HIV infection, while one had symptoms such as oral candidiasis and herpes zoster rash.

bIndirect HIV-1 EIA.




Fig. 1
Western blot profiles of sera from five individuals infected with HIV-2


Serum samples from subjects KR8091 (lane 1), KR7051 (lane 2), KR4075 (lane 3), KR4063 (lane 4), and KR1010 (lane 5) were analyzed for seroreactivity with HIV-1 antigen (A) and HIV-2 antigen (B). P and N, positive and negative controls, respectively.

# Analysis of serological profiles in HIV-2 infected subjects

Table 3 shows serological profiles for the five HIV-2-infected subjects which were diagnosed as positive by HIV-1/2 EIA, HIV-2 PA test and HIV-2 Western blot analysis. All the five sera were positive with titers over 1:16,384 in the HIV-2 PA test, while they were negative or indeterminate in the HIV-1 PA test and indeterminate in the HIV-1 Western blot analysis. Fig. 1 shows results of the Western blot analysis for HIV-1 and HIV-2 antigens. Three sera (KR4075, KR4063, and KR1010) showed a strong reactivity with synthetic HIV-2 gp36 in LIA but a weak or no reactivity with synthetic HIV-1 gp41. One serum (KR1010) displayed a weak signal in indirect HIV-1/2 EIA and was repeatedly negative in competitive HIV-1 EIA.

# Detection of HIV-2 infection by PCR

The nested PCR was used to characterize viral sequences in PBMC DNA from four subjects. As no PBMCs were obtained in the case of KR8091, we performed the nested PCR with cDNA obtained by RT-PCR. PBMC DNA and cDNA were amplified with the gag and env primer pairs known to detect HIV-2 sequences. However, the diagnostic HIV-2 gag primer pair failed to amplify viral sequences in samples from two subjects (KR4075 and KR1010). Also, these samples did not yield amplification signal with the env primer pair despite repeated attempts and various conditions for PCR. Therefore, in these two cases, we tried to amplify the gag and env region by RT-PCR from fresh plasma samples. However, PCR signals were obtained for the env region only. Interestingly, these two samples originated from the individuals with more than 500 CD4+






Fig. 2
Phylogenetic analysis based on sequences of parts of gag (A) and env (B) genes of HIV-2 isolates from South Korea (bold shaped) and those of reference HIV-2 strains obtained by blast search

In the gag tree, five HIV-2 subtypes (A,B,C,D, E) and in the env tree, two HIV-2 subtypes were available. The length of horizontal lines connecting one sequence to another is proportional to the divergence between the sequences.

Majority	SCDKHYWDAMR FRYCAPPG FALLRCNDTNYSG FEPNCSKVVASTCTRMMETQTSTW FGFNGTRAENRTYI YWHGK DNRTI	
IM 7051 0	TYTY	236
KR7051-2		238
KR7051-17	• •	238
KR4063-6		237
KR4063-11		862
CBL23	KAAAFR	
ALI	IYAAMRRRR	865
CBL24		877
CAM3	I	877
	ŢQ	7051
MDS	n t	6991
SBLISV		7020
ROD		6994
GH1		6982
NIHZ		
BEN	K.TAS	7577
CAM6	TSRRR	886
EHOA	SL	7536
UC1	SLY	7549
D205	SLFMSSSEE	7544
0203		
Majority	* ISLNKYYNLTIHCKRPGNKTVVPITLMSGLVFHSQ-P-INKRPRQAWCWFKGEWKEAMQEVKQTLAKHPRYKGT-NDTSN	
Hajority		
KR7051-2	YEKEKN.RD	467
KR7051-17	YEKN.RD	469
KR4063-6	F SL R R E R M R	469
		468
KR4063-11		1096
CBL23		1096
ALI		
CBL24		1108
CAM3	SL	1108
MDS	ASSL	7282
SBLISV	L.RERRKIKRRVVVNK	7225
ROD	SLI.KQ.MHHYQPKDE	7257
GH1	S	7225
NIHZ	NF M L F FK - V K E Q E NRSR.E.	7219
BEN		7808
		1117
CAM6		7767
EHOA		7780
UC1		7778
D205	· · · · · · · · · · · · · · · · · · ·	. , , ,
Majority	INFTA-PGKGSDPEVAYMWTNCRGEFLYCNMTWFLNWVENRTG-QTQRNYVPCHIKQIINTWHKVGKNVYLPPREGELTC	
		704
KR7051-2	.T.RR	704
KR7051-2 KR7051-17	T.RR	706
KR7051-2 KR7051-17 KR4063-6	T.RR. I. N.KH.A	706 703
KR7051-2 KR7051-17	T.RR. I. N.KH.A	706 703 702
KR7051-2 KR7051-17 KR4063-6	T.RR. I. N.KH.A. I. I. N.KH.A. I. I. N.KH.A. I. I. N.KH.A. I. N.	706 703 702 1321
KR7051-2 KR7051-17 KR4063-6 KR4063-11	T R R	706 703 702 1321 1330
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23	T R - R	706 703 702 1321 1330 1342
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24	T R - R	706 703 702 1321 1330
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI	T R - R	706 703 702 1321 1330 1342
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV	T R - R . I . N . KH . A	706 703 702 1321 1330 1342 1345 7516 7456
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ	T R - R . I . N . KH . A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6	TR - R I N KH A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033 1351
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033 1351 7998
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033 1351 7998 8014
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033 1351 7998
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033 1351 7998 8014
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1	TR - R	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033 1351 7998 8014
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033 1351 7998 8014
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7482 7459 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23	TRR. I. N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI	TR - R	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24	TR - R	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority  KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3	TRR. I.N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS	TRR. I.N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV	T.R R.	706 703 702 1321 1330 1342 1345 7516 7456 7459 7459 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD	T.RR. II N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8015 887 889 888 1507 1516 1528 1531 7702 7645 7645
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH2 ROD GH2 ROD GH2 ROD GH2 ROD GH2 ROD GH3 GH3 ROD GH3 GH3 ROD GH3 GH3 GH3 GH3 GH3 GH3 GH3 GH3	T.R R	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015  887 889 889 889 1507 1516 1528 1531 7702 7645
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ	T.RR. II N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7459 7459 7453 8033 1351 7998 8014 8015
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH2 ROD GH2 ROD GH2 ROD GH2 ROD GH2 ROD GH3 GH3 ROD GH3 GH3 ROD GH3 GH3 GH3 GH3 GH3 GH3 GH3 GH3	T.R R	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8015 887 889 888 1507 1516 1528 1531 7702 7645 7645 7671 7645
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority  KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6	T.RR. I. N.KH A	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015  887 889 889 889 1507 1516 1528 1531 7702 7645 7671 7645 7636 8225 1537
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN	T.RR. II. N.KH.A.  T.RR. II. N.KH.A.  K- K.	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8015 887 889 888 1507 1516 1528 1531 7702 7645 7645 7671 7645
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority  KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6	T.RR. II.N.KH.A	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015  887 889 889 889 1507 1516 1528 1531 7702 7645 7671 7645 7636 8225 1537
KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA UC1 D205 Majority KR7051-2 KR7051-17 KR4063-6 KR4063-11 CBL23 ALI CBL24 CAM3 MDS SBLISV ROD GH1 NIHZ BEN CAM6 EHOA	T.RR. II. N.KH.A.  T.RR. II. N.KH.A.  K- K.	706 703 702 1321 1330 1342 1345 7516 7456 7459 7453 8033 1351 7998 8014 8015

Fig. 3

c. as/mm³. Finally, PCR signals were obtained with three of the five samples with the HIV-2-specific gag primer pair as with all the five samples with the env primer pair in PC for RT-PCR. Table 4 shows the detection of HIV-2 infection by nested PCR in the five subjects. To investigate possible dual infection in those subjects with confirmed HIV-2 infection, we tried to amplify the 1191 bp env HIV-1 region (V1-V5 of gp120) from four PBMCs samples but we could not detect any amplification signal.

# HIV-2 sequencing and phylogenetic analysis

To investigate the HIV-2 genotype of the isolates from South Korea and to perform a more comprehensive phylogenetical analysis, we amplified by PCR the 1191 bp env region. Only two isolates (KR4063 and KR7051) gave a positive result. These two 1191 bp env fragments and the three 197 bp gag fragments mentioned before were cloned and sequenced. Most sequences were derived from one or two clones. The sequences of each isolate were aligned with those of the corresponding region of various HIV-2 subtypes in the database and phylogenetic relationships were analyzed. As shown in Fig. 2, the isolates KR4063, KR7051, and KR8091 clustered within the known subtype A based on gag and env alignments. The nucleotide variation of the examined HIV-2 isolates was of 12.8% to 13.1% for the 1191 bp env region and of 1.0% to 2.1% for the 197 bp gag region. Fig. 3 shows amino acid sequences of HIV-2 gp105 C2-C5 regions of KR7051 and KR4063.

# Discussion

It is essential for the establishment of HIV testing strategies for a country to elucidate the extent of HIV-1 and HIV-2 infection. In South Korea, a HIV-1 antibody test has been performed since 1985. In addition, HIV-2 antibody testing by a combined HIV-1/2 kit was started in 1990 by the National Institute of Health of South Korea and many laboratories including blood centers have performed HIV-2 antibody testing since 1992. However, detailed serological and genetical data on HIV-2 infection in South Korea have never been reported.

According to the HIV antibody testing strategy of our laboratory, we have found five HIV-2-seropositive subjects. We tried to confirm the HIV-2 infection not only by serological testing but also by genetical analysis. In all the five cases we confirmed a HIV-2 infection by the *env* PCR while only three of them were HIV-2-positive by the *gag* PCR. Earlier studies have shown that it was difficult to isolate HIV-2 from asymptomatic subjects because the proviral load could be very low (Berry *et al.*, 1994; Gao *et al.*, 1994; van der Ende *et al.*, 1996). A nested PCR can be repeatedly

Table 4. Detection of HIV-2 infection by nested PCR

	HIV-1		CD4 + T cell		
Subjects	<i>env</i> (1.2 kbp)	<i>gag</i> (197 bp)	<i>env</i> (137 bp)	<i>env</i> (1191 bp)	count <sup>c</sup> (cells/mm <sup>3</sup> )
KR8091	ND	+++p	+++b	ND	ND
KR7051	_	+++*	+++*	+++	121
KR4075			$+++_{p}$	-	643
KR4063	_	+++a	+++*	+++	423
KR1010	-	_	++6	_	885

"Signal intensity of PCR product.

bSignal intensity of RT-PCR product.

°CD4+ T cell count at that time of PCR.

ND = not done.

negative in some of HIV-2 patients (Damond *et al.*, 1998). Simon (1993) has reported that positive rate of cell and plasma virus content was related to the number of CD4+ cells because HIV-2 viral concentration correlated inversely with the number of CD4+ cells. Further study should be undertaken to elucidate whether the absence of signal in the *gag* region observed by us with the two isolates was related to CD4+ lymphocyte numbers or resulted from genetic variation of HIV-2. The two isolates, KR1010 and KR4075 that failed to produce *gag* PCR products were obtained form healthy patients at asymptomatic clinical stage as one had the CD4+T lymphocyte count of 885/mm³ and the other had that of 643/mm³ based on immunological tests at the time of blood sample collection. Therefore, low viral loads at the asymptomatic stage may lead to failure of PCR.

On the other hand, Ishikawa et al. (1998) regarded low HIV-2-positive rates as genetic variation of HIV-2. They confirmed 58 specimens from 68 persons as HIV-2-positive with HIV-2 primers of various nucleotide sequences and enhanced sensitivity by doubling the number of PBMCs for HIV-2 detection from individuals with HIV1/2 dual seroreactivity. However, additional factors should be considered to explain the lower rate of HIV-2 detection compared to that of HIV-1 despite similar genetic variation in env and gag regions of these viruses (Chen et al., 1997; Gao et al., 1994). In the case of HIV-1 env gene, the sensitivity of HIV-1 PCR was up to 100% in our laboratory even though the DNA samples were obtained from PBMCs of asymptomatic patients (data not shown). These data suggest that the low HIV-2 positivity by PCR is due to low viral load rather than high genetic variation.

Numbers of subjects evidenced as infected with HIV-2 in South Korea are one in 1991, two in 1994, one in 1997, and one in 1998. Two of these total five subjects were surveyed as wives or sexual partners of an HIV-2 infected person. Introduction of HIV-2 into South Korea started presumably in early 1990s. Presently, the number of HIV-2-

infected subjects is extremely small compared with 959 HIV-1-infected ones. Leonard *et al.* (1993) have suggested that the combination of serological and PCR tests is required for demonstration of the presence of HIV-2 DNA in dually seroreactive patients. Detection of more HIV-2 infections could be possible by investigating specimens showing positive reaction in both HIV-1 and HIV-2 PA test as well as more than two *env* proteins in HIV-2 Western blot analysis. In addition, the identification of subjects with HIV-2 demonstrates the necessity of including a HIV-2 test in HIV screening in South Korea especially in blood centers and quarantine stations.

Three South Korean HIV-2 isolates were classified as subtype A. Presumably these results are related to the epidemiological history of South Korea with HIV-2 of predominantly A subtype.

In conclusion, HIV-2 has been transmitted into South Korea before 1991 and the newly HIV-2-infected persons have appeared continuously. Therefore, the diagnosis of HIV infection should include the possibility of HIV-1 as well as HIV-2 based on the present transmission situation. Furthermore, our data obtained by genetic analysis of HIV-2 isolates suggest that further study is necessary for the improvement of HIV-2 diagnosis by PCR and development of HIV vaccines.

**Acknowledgement.** We thank Dr. Thomas C. Merigan, Dr. Elizabeth Johnston (Center for AIDS Research, Stanford University, USA) and Dr. Haewol Cho (National Institute of Health, Seoul, South Korea), for assistance in revising the English of the manuscript. This study was supported by the Intramural Fund of the National Institute of Health of South Korea.

## References

- Berry N, Ariyoshi K, Jobe O, Ngum PT, Corrah T, Wilkins A, Whittle H, Tedder R (1994): HIV type 2 proviral load measured by quantitative polymerase chain reaction correlates with CD4+ lymphopenia in HIV type 2-infected individuals. *AIDS Res. Hum. Retrovir.* **10**, 1031–1037.
- Chen Z, Luckay A, Sdora DL, Telfer P, Reed P, Gettie A, Kanu JM, Sadek RF, Yee J, Ho DD, Zhang L, Marx PA (1997): Human immunodeficiency virus 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. *J. Virol.* 71, 3953–3960.
- Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, Klatzmann D, Champalimaud JL, Montagnier L (1986): Isolation of a new human retrovirus from West African patients with AIDS. *Science* 233, 343–346.

- Damond F, Loussert-Ajaka I, Apetrei C, Descamps D, Souquiere S, Lepretre A, matheron S, Brun-Vezinet F and Simon F (1998): Highly Sensitive Method for Amplification of Human Immunodeficiency Virus Type 2 DNA. *J. Clin. Microbiol.* **36**, 809–811.
- De Cock KM, Adjorlolo G, Ekpini E *et al.* (1993): Epidemiology and transmission of HIV-2: why there is no HIV-2 pandemic. *JAMA* **270**, 2083–2086.
- Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, Neequaye AE, Whelan TM, Ho DD, Shaw GM, Sharp PM, Hahn BH (1994): Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. *J. Virol.* 68, 7433–7447.
- Grankvist O, Bredberg-Raden U, Gustafsson A, Albert J, Albino P, Andreasson PA, Naucler A, Biberfeld G, Wadell G (1992): Improved detection of HIV-2 DNA in clinical samples using a nested primer-based polymerase chain reaction. *AIDS* 5, 286–293.
- Ishikawa K, Fransen K, Ariyoshi K, Nkengasong JN, Janssens W, Heyndrickx L, Whittle H, Diallo MO, Ghys PD, Coulibaly I-M, Greenberg AE, Piedade PD, Canas-Ferreira W, van der Groen G (1998): Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCR. *AIDS* 12, 1419–1424.
- Kanki PJ, Travers KU, Mboup S, Hsish C-C, Marlink RG, Gueye-Ndiaye A, Siby T, Thior I, Hernandez-Avila M, Sankale J-L, Ndoye I, Essex ME (1994): Slower herterosexual spread of HIV-2 than HIV-1. *Lancet* 343, 943–946.
- Leonard G, Chaput A, Courgnaud V, Sangare A, Denis F, Brechot C (1993): Characterization of dual HIV-1 and HIV-2 serological profiles by polymerase chain reaction. AIDS 7, 1185–1189.
- Nakamura S, Katamine S, Yamamoto T, Foung SKH, Kurata T, Hirabayashi Y, Shimada K, Hino S, Miyamoto T (1993): Amplification and detection of a single molecule of human immunodeficiency virus. Virus Genes 7, 325– 338.
- Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh C-C, Dia MC, Gueye E-H, Hellinger J, Gueye-Ndiaye A, Sankale J-l, Ndoye I, Mboup S, Essex M (1994): Reduced rates of disease development after HIV-2 infection as compared to HIV-1. *Science* **265**, 1587–1590.
- Schim van der Loeff MF, Aaby P (1999): Towards a better understanding of the epidemiology of HIV-2. *AIDS* **13** (Suppl. A), S69–S84.
- Simon F, Matheron S, Tamalet C, Loussert-Ajaka L, Bartczak S, Pepin JM, Dhiver C, Gamba E, Elbim C, Gastaut JA, Saimot AG, Brun-Vezinet F (1993): Cellular and plasma viral load in patients infected with HIV2. *AIDS* 7, 1411–1417.
- van der Ende ME, Schutten M, Ly TD, Gruters RA, Osterhaus ADME (1996): HIV-2 infection in 12 European residents: virus characteristics and disease progression. *AIDS* **10**,1649–1655.